NPCE
NeuroPace, Inc.15.88
-0.04-0.25%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
528.93MP/E (TTM)
-Basic EPS (TTM)
-0.75Dividend Yield
0%Recent Filings
8-K
10-Q
10-Q
Q2 FY2025 results
NeuroPace's Q2 FY2025 10-Q filing highlights executive transitions, including the separation of Rebecca Kuhn as CFO effective June 20, 2025, with a 12-month severance package and consulting role through June 2026 to ensure continuity, alongside the appointment of Patrick Williams as new CFO starting July 3, 2025, at a $500,000 base salary and 60% target bonus. The company entered a $75 million credit facility with MidCap Funding on June 4, 2025, featuring a $60 million term loan and $15 million revolving line maturing June 4, 2030, to support working capital and general corporate needs. No financial statements or performance metrics are included in the provided excerpts, focusing instead on governance and financing updates. Regulatory risks persist, particularly around FDA approvals for medical devices.
8-K
Q2 revenue hits $23.5M
NeuroPace reported Q2 2025 revenue of $23.5 million, up 22% year-over-year, fueled by RNS System sales and manufacturing efficiencies that lifted gross margin to 77.1%. The company refinanced into a $75 million credit facility and raised full-year revenue guidance to $94–$98 million with 75–76% margins, while NAUTILUS study data showed 79% median seizure reduction in IGE patients. Momentum builds. CMS preserved reimbursement stability for RNS procedures.
8-K
CFO Transition at NeuroPace
NeuroPace announced on June 20, 2025, the departure of CFO Rebecca Kuhn, who transitions to a senior strategic advisor role through June 19, 2026, receiving 12 months of base salary severance, pro-rated 2025 bonus of $88,885, and continued equity vesting. The company appointed Patrick F. Williams, with over 25 years in medical device finance including stints at STAAR Surgical and Sientra, as new CFO, offering $500,000 base salary, 60% target bonus, and equity grants of 51,850 RSUs plus 87,950 options. This shift bolsters financial leadership amid growth opportunities for the RNS System. Transition smooths operations.
CBLL
CeriBell, Inc.
21.99+0.09
CLPT
ClearPoint Neuro Inc.
13.82+1.44
EBRCZ
EBR SYSTEMS INC NPV CDI 1:1
0.60+0.00
INSP
Inspire Medical Systems, Inc.
115.51-3.75
LIVN
LivaNova PLC
63.08+0.02
NMTC
NeuroOne Medical Technologies C
0.71+0.05
NXL
Nexalin Technology, Inc.
0.81-0.01
RMSL
RemSleep Holdings, Inc.
0.00+0.00
STIM
Neuronetics, Inc.
1.65-0.11
VYCO
Vycor Medical, Inc.
0.16+0.00